Wu Yong, Wu Yong-You, Li Shan, Zhu Bao-Song, Zhao Kui, Yang Xiao-Dong, Xing Chun Gen
Department of General Surgery, The Second Affiliated Hospital, Soochow University, Suzhou, China.
Hepatogastroenterology. 2011 Mar-Apr;58(106):364-8.
BACKGROUND/AIMS: To compare transanal endoscopic microsurgery (TEM) with conventional radical surgery (CRS) for T1 rectal cancer focusing on safety, feasibility and efficacy of both procedures.
An online search of Ovid, Medline, Embase, Pubmed and Cochrane Controlled Trials Register was undertaken to identify studies comparing TEM with CRS published in English between 1984 and March 2010. Only studies comparing TEM with CRS for T1 rectal cancer treatment and with a minimum of 20 cases were included. The parameters compared were postoperative complications, hospital mortality, recurrence rate and 5-year survival.
Five studies met screening criteria and 397 patients were enrolled in the meta-analysis; 216 were treated with TEM and the rest received CRS. Complications were observed in 16/196 in the TEM group and 77/163 in the CRS group. The difference was significant (p=0.01). The rate of mortality was 3.68% in CRS group, and 0 in TEM group (p=0.01). The 5-year survival was similar (p=0.84), the TEM group was 80.1% and the CRS group was 81.0%. However, there was more recurrence in the TEM group compared to CRS group (p=0.0004). TEM group was 12.0%, while CRS group was 0.5%.
Compared with CRS, TEM had significant shorter hospital stay and fewer postoperative complications. TEM is a safe, feasible and effective option for T1 rectal cancer. Though TEM had a slightly higher rate of recurrence than CRS, no significant difference on 5-year survival was observed.
背景/目的:比较经肛门内镜显微手术(TEM)与传统根治性手术(CRS)治疗T1期直肠癌的安全性、可行性和疗效。
通过在线检索Ovid、Medline、Embase、Pubmed和Cochrane对照试验注册库,以确定1984年至2010年3月间发表的比较TEM与CRS的英文研究。仅纳入比较TEM与CRS治疗T1期直肠癌且病例数至少为20例的研究。比较的参数包括术后并发症、医院死亡率、复发率和5年生存率。
五项研究符合筛选标准,397例患者纳入荟萃分析;216例接受TEM治疗,其余接受CRS治疗。TEM组196例中有16例出现并发症,CRS组163例中有77例出现并发症。差异有统计学意义(p = 0.01)。CRS组死亡率为3.68%,TEM组为0(p = 0.01)。5年生存率相似(p = 0.84),TEM组为80.1%,CRS组为81.0%。然而,TEM组的复发率高于CRS组(p = 0.0004)。TEM组为12.0%,而CRS组为0.5%。
与CRS相比,TEM的住院时间显著缩短,术后并发症更少。TEM是治疗T1期直肠癌的一种安全、可行且有效的选择。虽然TEM的复发率略高于CRS,但5年生存率无显著差异。